AKT1 and neoplasm: The common approaches to targeting CSCs are targeting their surface biomarkers such as CD133, CD44, CD24, ESA, CD47, targeting proliferative, stemness and EMT signaling pathways like Notch, Hedgehog, P13K/Akt, Wnt, and NFkB that regulate CSC self-renewal and differentiation [121], adjustment of the tumor microenvironment signals such as angiogenesis, hypoxia and acidic pH, inhibiting drug-efflux pumps, manipulation of miRNA expression, induction of CSCs apoptosis and differentiation, and induction of ferroptosis [122,123,124].